Form 4: Kura Oncology Chief Scientific Officer Acquires 185,000 Stock Options

Kura Oncology's Chief Scientific Officer, Francis Burrows, was granted options to purchase 185,000 shares of common stock.

Summary

• Francis Burrows, the Chief Scientific Officer of Kura Oncology, Inc., was granted an option to purchase 185,000 shares of the company's common stock.
• The options were granted on January 2, 2025, at an exercise price of $8.68 per share.
• The options vest in 48 equal monthly installments starting from the grant date.
• The options expire on January 1, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative sentiment.

Positives

• The grant of stock options to the Chief Scientific Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of compensation for executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry to incentivize key personnel.
• The vesting schedule of 48 months is typical for executive stock options.
• The exercise price is set at a specific value, which is common practice.

Stakeholder Impact

• The stock option grant may positively impact shareholder value if the executive's performance leads to company growth.
• The grant incentivizes the Chief Scientific Officer to contribute to the company's success.

Key Dates

Keywords

stock options, insider trading, executive compensation, Kura Oncology, Form 4, biotechnology